Revolutionizing AMD Treatment: The Development of an Anti-inflammatory Nimvec-based Gene Therapy for Dry Age-related Macular Degeneration

Time: 2:30 pm
day: Conference Day Two


  • Delving into vectors that are safe by design, non-immunogenic & tolerogenic in humans, inducing long-term transgene expression and can be repeatedly administered to deliver the same or different transgenes to target tissues
  • Analyzing gene replacement and immunotherapies options to treat genetic disorders and inflammatory/autoimmune diseases
  • Combining effective protection of macular cells from pyroptosis with regeneration of the damaged macula, resulting in the restoration of central vision